in 2023, a vaccine designed to be injected into tumours has been developed to restore STING signaling and eliminating the majority of tumors in mouse models of colon cancer and melanoma, with minimal side effects. The vaccine also inhibited metastasis in a breast cancer mouse model and prevented the recurrence of tumors in cured mice. CD8+ T cells, and, seemingly paradoxically, CD4+ T cells play pivotal roles in achieving this anti-tumour immunity. STING signaling polarized the CD4+ T cells into the T helper Type I (TH1) phenotype, a helper T cell that activates other immune cells to attack tumor cells. Such a vaccine administered systemically could have severe unwanted effects.
7)